Page 19 - bfs_book

Повлияването на менструалната мигрена от Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.
frovatriptan е доказана при съпоставката му с gov/books/NBK553159/
плацебо 34,35 . По всички показатели frovatriptan 15. Belvis R., Pagonabarraga J., Kulisevsky J. Individual triptan
selection in migraine attack therapy. Recent Pat CNS Drug Discov.
има статистически по-добри резултати. След 2009 Jan;4(1):70-81. DOI: 10.2174/157488909787002555.
2-рия час облекчението на болката е 37 - 46%, 16. Durgaprasad K., Gowri S., Chintapalli et all. (2022). Formulation
на 4-тия час е 56 - 65%, а на 4-ти час без болка and Evaluation of Triptans: A Critical Overview. High Technology
Letters. 28. 181-192. . DOI: 10.37896/HTL28.06/5914.
са 27 - 32 % от проследените пациенти. Същите 17. Eletriptan, NIH National Library of Medicine NCBI. Available
показатели проследени при плацебо групата from: https://pubchem.ncbi.nlm.nih.gov/compound/Eletriptan
са съответно 21 - 27%; 31 - 38% и 9 - 14% 34,35 . 18. Sumatriptan, NIH National Library of Medicine NCBI. Available
from: https://pubchem.ncbi.nlm.nih.gov/compound/5358
Лечението на мигренозен пристъп с frovatriptan 19. Frovatriptan, NIH National Library of Medicine NCBI. Available
е ефективно и добре толерирано. Активното ве- from: https://pubchem.ncbi.nlm.nih.gov/compound/77992
щество съчетава по-продължителен ефект, с 20. Eletriptan (Monograph) Available from: https://www.drugs.
com/monograph/eletriptan.html
по-малко НЛР и високи нива на поносимост . Въве- 21. Frovatriptan (Monograph), Available from: https://www.drugs.
ден за първи път в България, frovatriptan дава нови com/monograph/frovatriptan.html
терапевтични възможности за лечение в страната. 22. Allais G., Benedetto C. A review of the use of frovatriptan in the
treatment of menstrually related migraine. Ther Adv Neurol Disord.
2013 Mar;6(2):55-67. DOI: 10.1177/1756285612470191.
Използвани източници: 23. Antonaci, F., Ghiotto, N., Wu, S. et al. Recent advances in
1. Фармакотерапевтично ръководство за лечение на не- migraine therapy. SpringerPlus 5, 637 (2016). DOI: 10.1186/s40064-
врологичните заболявания, Available from: https://www. 016-2211-8
mh.government.bg/media/filer_public/2019/04/01/ftr_za_ 24. Sumatriptan (Monograph), Available from: https://www.drugs.
lechenie_na_nevrologichnite_zaboliavaniia.pdf com/monograph/sumatriptan.html
2. National Consensus on Diagnosis and Treatment of Primary 25. КХП - Кратки характеристики на продуктите - Официална
Headaches., (2018) Том 20 – 1 Chephalagia, ISSN 1311-3623 страница на Изпълнителната агенция по лекарствата към Ми-
3. Khan K., Ibrahim Al Asoom L., Al Sunni A., et al.. Genetics, нистерството на Здравето на Република България, Available
pathophysiology, diagnosis, treatment, management, and from: https://www.bda.bg/bg/ регистри/кратки-характеристи-
prevention of migraine, Biomedicine & Pharmacotherapy, Volume ки-на-продуктите
139, 2021, 111557, ISSN 0753-3322, DOI: 10.1016/j.biopha.2021.111557 26. Кратка характеристика на продукта – Avoran, Available
4. Agbetou M. & Adoukonou T. (2022). Lifestyle Modifications from: https://www.bda.bg/images/stories/documents/bdias/2023-
for Migraine Management. Frontiers in Neurology. 13. 719467. 03-21-131122.pdf
DOI:10.3389/fneur.2022.719467. 27. Cady R., Elkind A., Goldstein J., Keywood C. (2004) Randomized,
https://pubmed.ncbi.nlm.nih.gov/19149716/ placebo-controlled comparison of early use of frovatriptan in a
5. Chaushev N., Milanov I. (2011). Quality of life in Bulgarian patients migraine attack versus dosing after the headache has become
with migraine Cephalgia. 14. 35-42. moderate or severe, Current Medical Research and Opinion, 20:9,
6. International Headache Society, HIS Classification ICHD-3, 1465-1472, DOI: 10.1185/030079904X2745
Migraine, Available from: https://ichd-3.org/1-migraine/ 28. Zheng H., Xia Y., Qu S et al. Pharmacokinetic Study of Frovatriptan
7. Qamariat Z. (2021). Rational and Irrational Drug Use: Factors, Succinate Tablet After Single and Multiple Oral Doses in Chinese
Impacts and Strategies to Combat Irrational Drug Use: A Narrative Healthy Subjects. Drug Des Devel Ther. 2021 Jul 7;15:2961-2968. DOI:
Review. International Journal of Pharmaceutical Sciences and 10.2147/DDDT.S308958.
Clinical Pharmacy. 2. 6-17. DOI:10.47890/IJPSCP/ZahraHassanALQ 29. Sanford M. Frovatriptan: a review of its use in the acute
amariat/2021/24148307. treatment of migraine. CNS Drugs. 2012 Sep 1;26(9):791-811. DOI:
8. National Headache Foundation, Headache Tests Available from: 10.2165/11209380-000000000-00000
https://headaches.org/resources/headache-tests/ 30. Cady R. Farmer K. (2016). Managing migraine by patient profile:
9. Milanov I. (2011). Validity and reliability of the Bulgarian version Role of frovatriptan. Patient Preference and Adherence. 10. 501.
of the migraine disability assessment (MIDAS) questionnaire. DOI:10.2147/PPA.S85795.
Cephalgia. 13. 6-10. 31. Negro A., Lionetto L., Casolla B., Lala N., Simmaco M., Martelletti
10. Stewart W., Lipton R., Kolodner K. et all. (2000). Validity of the P. (2011) Pharmacokinetic evaluation of frovatriptan, Expert
Migraine Disability Assessment (MIDAS) Score in comparison to a Opinion on Drug Metabolism & Toxicology, 7:11, 1449-1458, DOI:
diary-based measure in a population sample of migraine sufferer. 10.1517/17425255.2011.622265
Pain. 88. 41-52. DOI:10.1016/S0304-3959(00)00305-5. 32. Tullo V., Valguarnera F., Barbanti P., et al.. (2013). Comparison of
11. Evers, S., Afra, J., Frese, A., et al.. (2009). EFNS guideline on the frovatriptan plus dexketoprofen (25mg or 37.5 mg) with frovatriptan
drug treatment of migraine - revised report of an efns task force. alone in the treatment of migraine attacks with or without aura:
European Journal of Neurology, 16(9), 968-981. DOI: 10.1111/j.1468- A randomized study. Cephalalgia : an international journal of
1331.2009.02748.x headache. 34. DOI: 10.1177/0333102413515342.
12. Наредба № 7 от 3 октомври 2019 г. За приемане на фарма- 33. Allais G., Tullo V., Cortelli P. et al. (2014). EHMTI-0052. Efficacy of
ко-терапевтично ръководство за лечение на неврологичните за- early vs. late use of frovatriptan combined with dexketoprofen vs.
болявания, изм. - ДВ, бр. 45 от 2023 г. frovatriptan alone in the acute treatment of migraine attacks with
13. Silberstein S., Holland S., Freitag F., et. Al. Evidence-based or without aura. Neurological Sciences. 35 Suppl 1. DOI: 107-13.
guideline update: Pharmacologic treatment for episodic migraine 10.1007/s10072-014-1751-3.
prevention in adults Report of the Quality Standards Subcommittee 34. MacGregor A. (2014). A review of frovatriptan for the treatment
of the American Academy of Neurology and the American of menstrual migraine. International journal of women‘s health. 6.
Headache Society. Neurology Apr 2012, 78 (17) 1337-1345; DOI: 523-535. DOI:10.2147/IJWH.S63444.
10.1212/WNL.0b013e3182535d20 35. Allais G., Benedetto C. (2016). Spotlight on frovatriptan: A review of
14. Lew C, Punnapuzha S. Migraine Medications. [Updated 2023 its efficacy in the treatment of migraine. Drug Design, Development
May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls and Therapy. 10. 3225-3236. DOI:10.2147/DDDT.S105932.

19